Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Schlumbrecht on Remaining Challenges in Uterine Leiomyosarcoma

January 16th 2020

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

PARP Inhibitors Gain Importance in Ovarian Cancer Lineup

January 15th 2020

PARP inhibitors are poised to acquire a stronger foothold in the frontline setting for advanced ovarian cancer, for which chemotherapy remains the backbone of treatment, according to a panel of gynecologic oncology experts who discussed the issue during an OncLive Peer Exchange® held during the European Society for Medical Oncology Congress 2019.

Dr. Hays on Immunotherapy in Ovarian Cancer Treatment

January 15th 2020

John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.

Addressing Fatigue as an Adverse Event in Ovarian and Uterine Cancers

January 14th 2020

Hanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.

FDA Grants Priority Review to Olaparib Plus Bevacizumab as Frontline Maintenance in Ovarian Cancer

January 13th 2020

The FDA has granted a priority review designation to a supplemental new drug application for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab.

Dr. Schlumbrecht on the Role of Surgical Resection in Uterine Leiomyosarcoma

January 13th 2020

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Dr. Backes on the FILM Trial in Endometrial Cancer

January 9th 2020

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

Dr. Schlumbrecht on the Challenges of Diagnosing Uterine Leiomyosarcoma

January 9th 2020

Matthew P. Schlumbrecht, MD, discusses ongoing challenges in diagnosing uterine leiomyosarcoma.

Dr. Hellmann on Sentinel Lymph Node Mapping in Endometrial Cancer

December 19th 2019

Mira Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the use of sentinel lymph node mapping in patients with endometrial cancer.

Dr. Hellmann on Evolution of Surgical Techniques in Endometrial Cancer

December 18th 2019

Mira Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the evolution of surgical techniques in endometrial cancer.

Dr. Cosgrove on Retreatment With PARP Inhibitors in Ovarian Cancer

December 18th 2019

Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.

Dr. Ferguson on Minimally Invasive Vs Open Surgery for Radical Hysterectomy in Cervical Cancer

December 17th 2019

Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.

Olaparib Approved in China for Frontline Maintenance in Ovarian Cancer

December 5th 2019

China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

UK Expands Olaparib Maintenance Indication in Ovarian Cancer

December 3rd 2019

The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.

Recent Data Muddle Role of Secondary Surgery in Recurrent Ovarian Cancer

December 3rd 2019

Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.

A Society That Worries About Risks Should Consider Cancer Prevention

November 23rd 2019

When discussing the topic of vaccination to prevent serious childhood illness, an increasing number of individuals refuse to accept the unequivocally demonstrated value of this public health strategy despite the very low risk of harm.

Real-World Evidence Reassuring for PARP Inhibitor Use in Ovarian Cancer

November 22nd 2019

Floor J. Backes, MD, discusses subtle differences among PARP inhibitors that can help determine their optimal use in advanced ovarian cancer.

Combos Could Unlock Major Immunotherapy Benefits in Ovarian Cancer

November 22nd 2019

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Expert Shares Insight on Evolution of Ovarian Cancer Therapeutics

November 21st 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

Dr. Salani Discusses Potential Treatment Modalities in Cervical Cancer

November 21st 2019

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.